Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $32.71

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $31.25.

Several equities analysts have recently weighed in on FDMT shares. Chardan Capital reissued a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Jefferies Financial Group reaffirmed a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Finally, Barclays started coverage on shares of 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective for the company.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FDMT. Dynamic Technology Lab Private Ltd purchased a new position in 4D Molecular Therapeutics during the first quarter valued at approximately $39,000. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at about $41,000. Quadrature Capital Ltd bought a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth approximately $42,000. Farther Finance Advisors LLC grew its holdings in 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after purchasing an additional 2,674 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth $46,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Stock Up 8.6%

Shares of FDMT opened at $9.31 on Friday. The business has a 50-day simple moving average of $8.98 and a two-hundred day simple moving average of $9.26. The stock has a market cap of $475.28 million, a price-to-earnings ratio of -3.85 and a beta of 2.99. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.96. The business had revenue of $85.09 million during the quarter, compared to analyst estimates of $30.86 million. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%. On average, equities analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.